Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease.
Shimura
Masahiko
M
Yasuda
Kanako
K
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003925:Diabetic Angiopathies / Q000150:complications; D005260:Female; D006801:Humans; D007511:Ischemia / Q000139:chemically induced*; D008266:Macula Lutea / Q000098:blood supply*; D008297:Male; D012170:Retinal Vein Occlusion / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab